A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Abstract

Objectives: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients.

Methods: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. The study was designed to determine if the drug had a response rate of at least 20% or 6-month PFS of at least 25%.

Results: Of 35 patients enrolled, 30 were treated and eligible (median age: 51, range: 27-73). Twenty-five (83%) were White, 4 (13%) Asian, and 1 (3%) unknown. The majority 28 (83%) patients, underwent ≤3 but 2 (7%) had 16 courses of study therapy. Five (16.7%) patients had PFS ≥6 months (90% CI: 6.8%-31.9%). Two (6.7%) patients had a partial or complete response (90% CI: 1.2%-19.5%). The median PFS was 2.7 months. The median overall survival was 12.8 months. The most common grade 3 adverse events were fatigue (4), hypertension (4), neutropenia (4), anemia (3), abdominal pain (3), and leukopenia (3). Grade 4-5 adverse events included: thrombocytopenia (5), anemia (2), acute kidney Injury (1), stroke (1), and allergic reaction (1).

Conclusion: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992.

Keywords: Persistent or recurrent clear cell ovarian carcinoma; Progression-free survival; Sunitinib.

Conflict of interest statement

Conflicts of interest

Dr. Monk discloses that St. Joseph’s Hospital institution has received research grants from Novartis, Amgen, Lilly Genentech, Janssen/Johnson & Johnson, Array, TESARO, and Morphotek. He has received honoraria for speaker bureaus from Roche/Genentech, AstraZeneca, Janssen/Johnson & Johnson, Myriad, TESARO, and Clovis. Additionally, Dr. Monk has been a consultant for Roche/Genentech, Merck, TESARO, AstraZeneca, Gradalis, Advaxis, Cerulean, Amgen, Vemillion, ImmunoGen, Pfizer, Bayer, NuCana, Insys, GlaxoSmithKline, Verastem, Mateon (formally OxiGENE), PPD, Clovis, Precision Oncology, Biodesix, Perthera, ImmunoGen and Cue. Dr. Chan disclose that he has received honoraria for speaker bureaus and/or consultation fees from Roche/Genentech, AstraZeneca, Tesaro, and Clovis.

Copyright © 2018. Published by Elsevier Inc.

Figures

Fig. 1.

Progression-free and Overall Survival.